The development of pro-apoptotic cancer therapeutics

Noha I. Ziedan; Hachemi Kadri; Andrew D. Westwell

doi:10.2174/138955708784567430

The development of pro-apoptotic cancer therapeutics

Noha I. Ziedan, Hachemi Kadri, Andrew D. Westwell

Cardiff University

Research output: Contribution to journal › Article › peer-review

Abstract

Resistance to apoptosis is one of the fundamental hallmarks of cancer. Recently, the selective induction of apoptosis in cancer cells has emerged as an exciting possibility for the development of future selective cancer therapy. This review will summarise the development of the major classes of small molecule "pro-apoptotic" antitumour agents.

Original language	English
Pages (from-to)	711-718
Journal	Mini-Reviews in Medicinal Chemistry
Volume	8
Issue number	7
DOIs	https://doi.org/10.2174/138955708784567430
Publication status	Published - 30 Jun 2008

Keywords

Pro-apoptotic cancer therapy
selective antitumour agents
apoptosis
small molecules
mitochondria-targeting
Xlinked inhibitor of apoptosis (XIAP)
B-cell lymphoma 2 (Bcl-2)
aerobic glycolysis
Allied health professions and studies

Access to Document

10.2174/138955708784567430

Cite this

@article{c74565fa8ca64de3b655c06dcd97ea57,

title = "The development of pro-apoptotic cancer therapeutics",

abstract = "Resistance to apoptosis is one of the fundamental hallmarks of cancer. Recently, the selective induction of apoptosis in cancer cells has emerged as an exciting possibility for the development of future selective cancer therapy. This review will summarise the development of the major classes of small molecule {"}pro-apoptotic{"} antitumour agents.",

keywords = "Pro-apoptotic cancer therapy, selective antitumour agents, apoptosis, small molecules, mitochondria-targeting, Xlinked inhibitor of apoptosis (XIAP), B-cell lymphoma 2 (Bcl-2), aerobic glycolysis, Allied health professions and studies",

author = "Ziedan, \{Noha I.\} and Hachemi Kadri and Westwell, \{Andrew D.\}",

year = "2008",

month = jun,

day = "30",

doi = "10.2174/138955708784567430",

language = "English",

volume = "8",

pages = "711--718",

journal = "Mini-Reviews in Medicinal Chemistry",

issn = "1389-5575",

publisher = "Bentham Science Publishers",

number = "7",

}

TY - JOUR

T1 - The development of pro-apoptotic cancer therapeutics

AU - Ziedan, Noha I.

AU - Kadri, Hachemi

AU - Westwell, Andrew D.

PY - 2008/6/30

Y1 - 2008/6/30

N2 - Resistance to apoptosis is one of the fundamental hallmarks of cancer. Recently, the selective induction of apoptosis in cancer cells has emerged as an exciting possibility for the development of future selective cancer therapy. This review will summarise the development of the major classes of small molecule "pro-apoptotic" antitumour agents.

AB - Resistance to apoptosis is one of the fundamental hallmarks of cancer. Recently, the selective induction of apoptosis in cancer cells has emerged as an exciting possibility for the development of future selective cancer therapy. This review will summarise the development of the major classes of small molecule "pro-apoptotic" antitumour agents.

KW - Pro-apoptotic cancer therapy

KW - selective antitumour agents

KW - apoptosis

KW - small molecules

KW - mitochondria-targeting

KW - Xlinked inhibitor of apoptosis (XIAP)

KW - B-cell lymphoma 2 (Bcl-2)

KW - aerobic glycolysis

KW - Allied health professions and studies

U2 - 10.2174/138955708784567430

DO - 10.2174/138955708784567430

M3 - Article

C2 - 18537726

SN - 1389-5575

VL - 8

SP - 711

EP - 718

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

IS - 7

ER -

The development of pro-apoptotic cancer therapeutics

Abstract

Keywords

Access to Document

Fingerprint

Cite this